APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

$45.43  +0.21 (0.46%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/09/2017
Outstanding shares:  106,521,818
Average volume:  803,344
Market cap:   $4,816,916,610
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYTQ6X1
Valuation   (See tab for details)
PE ratio:   -6.90
PB ratio:   10.46
PS ratio:   59.51
Return on equity:   -151.79%
Net income %:   -866.81%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy